Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
All-cause mortality
RCT	20,536 people with CHD, other occlusive arterial disease, or diabetes mellitus; 6748 people with peripheral arterial disease and 2701 people with peripheral arterial disease but without diagnosed CHD	Rate of all-cause mortality 1328/10,269 (13%) with simvastatin 40 mg daily 1507/10,267 (15%) with placebo	P = 0.0003	Effect size not calculated	Simvastatin 40 mg daily
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	All-cause mortality 1/120 (0.8%) with atorvastatin 80 mg daily 1/114 (0.9%) with placebo	Significance not assessed
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	All-cause mortality 4/120 (3%) with atorvastatin 10 mg daily 1/114 (1%) with placebo	Significance not assessed
RCT	10,305 people with hypertension; 514 (5%) with peripheral arterial disease	Rate of all-cause mortality median follow-up of 3.3 years 185/5168 (3.6%) with atorvastatin 10 mg daily 212/5137 (4.1%) with placebo	HR 0.87 95% CI 0.71 to 1.06		Not significant
Cardiovascular mortality
RCT	20,536 people with CHD, other occlusive arterial disease, or diabetes mellitus; 6748 people with peripheral arterial disease and 2701 people with peripheral arterial disease but without diagnosed CHD	Rate of cardiovascular mortality 587/10,269 (6%) with simvastatin 40 mg daily 707/10,267 (7%) with placebo	P = 0.0005	Effect size not calculated	Simvastatin 40 mg daily
RCT	10,305 people with hypertension; 514 (5%) with peripheral arterial disease	Rate of cardiovascular mortality median follow-up of 3.3 years 74/5168 (1.4%) with atorvastatin 10 mg daily 82/5137 (1.6%) with placebo	HR 0.90 95% CI 0.66 to 1.23		Not significant